Top Story - Biocon seals Rs 1,550 crore pact with Pfizer

19 Oct 2010 Evaluate

Biocon has entered into a $350-million (Rs 1,550 crore) strategic alliance with drug-major Pfizer on marketing Biocon’s insulin products. The agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insulin, glargine, aspart and lispro,. 

Under the terms of the agreement, Pfizer will make upfront payments of $200 million. Biocon is also eligible to receive an additional development and regulatory milestone payment of up to $150 million. In addition to the $350 million, the company will also receive additional payments linked to Pfizer’s sales of its four insulin biosimilar products across global markets. The company will launch recombinant human insulin in emerging markets in the first phase and then introduce it in Europe in 2012 with the timeline for introduction in the US in 2015

The potential market for these four products, according to Kiran Mazumdar Shaw , chairman and MD of Biocon, would roughly be around $20 billion by 2015. Biocon hopes to combine the synergies of Pfizer’s marketing and distribution networks and its own cost-effective developing and manufacturing capabilities to grab a piece of the $14-billion biosimilar market. 

crackcrack

Biocon Share Price

340.95 4.95 (1.47%)
10-Jun-2024 13:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1510.55
Dr. Reddys Lab 6127.90
Cipla 1526.50
Zydus Lifesciences 1082.30
Lupin 1626.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.